Brief: Context Therapeutics Expects To Enroll First Patient Mid-2024
02/05/2024 12:42
May 2 (Reuters) - Context Therapeutics Inc CNTX.O :
* CONTEXT THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND
APPLICATION
FOR A PHASE 1 CLINICAL TRIAL OF CTIM-76
* CONTEXT THERAPEUTICS: COMPANY EXPECTS TO ENROLL FIRST
PATIENT IN
MID-2024
Source text for Eikon: ID:nGNX4KNhz2
Further company coverage: CNTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Context Therapeutics
See all newsContext Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Context Therapeutics Q2 net loss widens on higher R&D costs
Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202